SynthesisDrug design, development and therapy2019

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.

Ziqi Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.